Effects of Ginseng Consumption on Cardiovascular Health Biomarkers in Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8339 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Phytotherapy Research, 2024. Verfasst von Xiao-Feng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Panax, Randomized Controlled Trials as Topic, Biomarkers, Blood Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 131 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Major Collaborative Innovation Project of Nanyang City, Henan Province, China.
Abstract (Originalsprache)
Ginseng, with various pharmacological activities, has received increasing attention to improve cardiovascular health (CVH). Therefore, this meta‐analysis synthesized the effect of ginseng consumption on biomarkers of CVH in adults. A systematic search was performed in the databases of PubMed, Scopus, Web of Science, Embase, and the Cochrane Library through July 24, 2023 to screen out English‐language randomized controlled trials (RCTs) evaluating the effects of ginseng consumption on body composition, blood pressure, vascular stiffness, lipid metabolism, glucose metabolism, insulin resistance, inflammatory cytokines, and adipocytokines in adults. The weighted mean difference (WMD) and 95% confidence interval (CI) were used to evaluate the overall effect size, and STATA 12.0 was used for comprehensive analysis. Forty‐five studies were included in the meta‐analysis. Ginseng consumption significantly reduced systolic blood pressure (SBP) (WMD = −2.57 mmHg, 95% CI = −4.99 to −0.14, p = 0.038), total cholesterol (TC) (WMD = −4.40 mg/dL, 95% CI = −8.67 to −0.132, p = 0.043), low density lipoprotein cholesterol (LDL‐C) (WMD = −2.81 mg/dL, 95% CI = −4.89 to −0.72, p = 0.008), C‐reactive protein (CRP) (WMD = −0.41 mg/L, 95% CI = −0.73 to −0.10, p = 0.010), and interleukin‐6 (IL‐6) (WMD = −2.82 pg./mL, 95% CI = −4.31 to −1.32, p < 0.001). Subgroup analyses suggested that supplementation with ginseng for less than 12 weeks significantly reduced SBP, but 12 weeks or more improved TC and CRP. Ginseng consumption on SBP, TC, and CRP seemed to be more effective on unhealthy participants. The meta‐analysis showed that ginseng consumption might have the potential to improve SBP, TC, LDL‐C, CRP, and IL‐6. These findings suggest that ginseng is a potential candidate for the maintenance of CVH. However, our results had high heterogeneity. Future high‐quality studies are needed to firmly establish the clinical efficacy of ginseng consumption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: Xiao-Feng Zhang, Rui-Xue Min, Zhen Wang, Yue Qi, Ruo-Nan Li, Jian-Ming Fan
Förderung
- National Natural Science Foundation of China
- Major Collaborative Innovation Project of Nanyang City, Henan Province, China
Zitieren
APA
Zhang, X. F., Min, R. X., Wang, Z., Qi, Y., Li, R. N., & Fan, J. M. (2024). Effects of Ginseng Consumption on Cardiovascular Health Biomarkers in Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Phytotherapy Research. https://doi.org/10.1002/ptr.8339
Vancouver
Zhang XF, Min RX, Wang Z, Qi Y, Li RN, Fan JM. Effects of Ginseng Consumption on Cardiovascular Health Biomarkers in Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Phytotherapy Research. 2024. doi:10.1002/ptr.8339
BibTeX
@article{Zhang2024,
author = {Zhang, Xiao-Feng and Min, Rui-Xue and Wang, Zhen and Qi, Yue and Li, Ruo-Nan and Fan, Jian-Ming},
title = {Effects of Ginseng Consumption on Cardiovascular Health Biomarkers in Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8339}
}
EUVIMED